Doxorubicin Market - Historic Data (2019-2024), Global Trends 2025, Growth Forecasts 2037
Doxorubicin Market in 2025 is estimated at USD 1.07 billion. The global Market size was valued at more than USD 1.01 billion in 2024 and is expected to register a CAGR of over 7.1%, exceeding USD 2.46 billion revenue by 2037. North America is set to surpass USD 861 million by 2037, fueled by rising prevalence of breast cancer and government initiatives for cancer research.
The growth of the market can be attributed to the increasing prevalence of cancer worldwide along with the significant investments in research and development of doxorubicin. The World Health Organization reported that cancer caused nearly 10 million deaths worldwide in 2020. In 2020, breast cancer accounted for 2.26 million cases, lung cancer was 2.21 million, colon and rectal cancer was 1.93 million, prostate cancer was 1.41 million, skin cancer was 1.20 million, and stomach cancer was 1.09 million. As the number of people diagnosed with cancer continues to rise, there is a higher demand for treatments such as doxorubicin, which is an effective form of chemotherapy. Doxorubicin is an anti-cancer drug that works by targeting and destroying cancer cells while leaving healthy cells intact.
In addition to these, factors that are believed to fuel the market growth of doxorubicin include increasing penetration of doxorubicin in emerging countries, the growing number of clinical trials, and increasing investments in oncology research. Moreover, the rise in the number of people suffering from leukemia, a type of cancer affecting the blood and bone marrow is expected to drive market growth. In 2023, the American Cancer Society estimates about 59,610 new cases of leukemia (all types) and 23,710 deaths associated with leukemia will be reported, as well as approximately 20,380 new cases of acute myeloid leukemia (AML) registered. Doxorubicin is used to treat a variety of blood cancers, such as acute myeloid leukemia and Hodgkin's lymphoma. It works by disrupting the production of proteins that cancer cells need to survive.
Doxorubicin Sector: Growth Drivers and Challenges
Growth Drivers
- Rising Incidence of Ovarian Cancer - Ovarian cancer is an aggressive form of cancer with a high mortality rate. American Cancer Society projection indicates that, as of 2023, approximately 19,710 new cases of ovarian cancer will be diagnosed and approximately 13,270 cases of ovarian cancer will be fatal. Doxorubicin, a chemotherapy drug, is one of the most commonly used medications for treating ovarian cancer. It works by interfering with the cell's DNA, which prevents the cancer cells from replicating and growing.
- Increasing Number of Approvals of Doxorubicin by Regulatory Authorities, such as the US Food and Drug Administration (FDA) - For instance, Zydus Cadila received approval from the US FDA in September 2020 for its generic Doxorubicin Hydrochloride Liposome injection, used to treat certain cancers, to be marketed across the United States.
- Rapid Surge in Healthcare Expenditures - Healthcare expenditures have been steadily increasing owing to rising medical costs, an aging population, and an increase in the number of people with chronic health conditions. As per the Centers for Medicare & Medicaid Services, the US National Health Expenditures in 2021 increased by 2.7% to USD 4.3 trillion, representing 18.3% of the GDP. There was an increase of 7.8% in prescription drug spending in 2021 to USD 378.0 billion, which is faster than the 3.7% increase that was recorded in 2020.
- Rising Geriatric Population Worldwide - For instance, according to the World Ageing Report 2019, there is an expectation that the number of people over the age of 65 is going to increase from 53.340 million in 2019 to 83.813 million by 2050. The geriatric population is more prone to various diseases such as cancer, and as a result, they require more medical intervention. Doxorubicin is an effective chemotherapy drug used to treat a variety of cancers and is therefore in high demand among the geriatric population.
- Rise in Government Initiatives for Cancer Awareness - For instance, as part of the National Comprehensive Cancer Control Program of the United States, funding, guidance, and technical assistance were provided in 2020 for the implementation of cancer prevention and control programs. also, the Government of India initiated the National Cancer Grid (NCG) in partnership with the Department of Atomic Energy and its grant-in-aid institution, the Tata Memorial Centre, to develop a national network for cancer treatment, including cancer research institutes, patient groups, and charitable organizations.
Challenges
- The high cost of doxorubicin and its severe side effects - Doxorubicin is a highly toxic chemotherapy drug, so its cost is understandably high. Its side effects can be debilitating, and its use is limited to the most serious cases. This restricts the market for it, as many patients are unable to afford it or are not willing to take the risk of potential side effects.
- Strict regulations imposed by various governments and the lack of reimbursement
- Availability of generic alternatives
Doxorubicin Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.1% |
|
Base Year Market Size (2024) |
USD 1.01 billion |
|
Forecast Year Market Size (2037) |
USD 2.46 billion |
|
Regional Scope |
|
Doxorubicin Segmentation
Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
The global doxorubicin market is segmented and analyzed for demand and supply by distribution channel into hospital pharmacy, retail pharmacy, and online pharmacy. Out of these, the hospital pharmacy segment is estimated to gain the largest market share of about 41% in the year 2037. The growth of the segment can be attributed to the increasing demand for hospital services and the availability of cost-effective drugs. The rising number of private hospitals, which are equipped with advanced technology and well-trained healthcare professionals, is also driving the growth of this segment. It was observed that currently, India is home to more than 43,480 private hospitals. As of 2020, France was home to 670 private not-for-profit hospitals and 970 private for-profit hospitals, while the United States had over 1574 private for-profit hospitals. Additionally, the availability of generic drugs, which are more affordable than brand-name drugs, is also contributing to the increased demand for hospital pharmacy products.
Drug Formulation (Lyophilized Powder, Injection)
The global market is segmented and analyzed for demand and supply by drug formulation into lyophilized powder and doxorubicin injection. Out of these, the doxorubicin injection segment is estimated to gain a significant market share of about 67% in the year 2037. The growth of the segment can be attributed to the increasing prevalence of cancer and other life-threatening diseases, combined with the growing demand for doxorubicin injections as a primary treatment for cancer. Additionally, the availability of various forms of doxorubicin injections, such as liposomal and hybrid formulations, is also contributing to the growth of the segment. Moreover, the rising demand for improved treatment outcomes and the emergence of targeted cancer therapies with doxorubicin injections have further increased the demand for doxorubicin injections.
Our in-depth analysis of the global market includes the following segments:
|
By Drug Formulation |
|
|
By Application |
|
|
By Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportDoxorubicin Industry - Regional Synopsis
North American Market Forecast
The market share of doxorubicin in North America, amongst the market in all the other regions, is projected to be the largest with a share of about 35% by the end of 2037. The growth of the market can be attributed majorly to the rising prevalence of breast cancer and its treatment, increasing government initiatives for cancer research, and increasing investments in research and development for new treatments for breast cancer are expected to support the growth of the market in North America. As per the Centers for Disease Control and Prevention findings, every year, approximately 264,000 cases of breast cancer are diagnosed in women and 2,400 in men in the United States. A total of 42,000 women and 500 men in the United States die from breast cancer each year. Doxorubicin is an effective chemotherapeutic agent that works by blocking the growth and reproduction of cancer cells. It has been used in the treatment of breast cancer for many years and is effective in shrinking tumors and prolonging the lives of patients. Additionally, factors such as the availability of healthcare infrastructure and the presence of leading market players in the region are also likely to contribute to the growth of the market in the region.
APAC Market Statistics
The Asia Pacific doxorubicin market is estimated to be the second largest, registering a share of about 27% by the end of 2037. The growth of the market can be attributed majorly to the increasing prevalence of cancer and the rise in demand for targeted therapies in the region. Targeted therapies are treatments that are tailored to the specific genetic makeup of an individual's cancer. This type of therapy is more effective and has fewer side effects than traditional treatments such as chemotherapy. Therefore, increased demand for targeted therapies is expected to drive the growth of the Asia Pacific market. Additionally, the rise in the number of regulatory approvals for doxorubicin-based drugs an increase in the number of clinical trials, and the development of innovative drug delivery models are further expected to drive the growth of the Asia Pacific doxorubicin market in the coming years.
Europe Market Forecast
Further, the market in Europe, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2037. The growth of the market can be attributed majorly to the increased prevalence of multiple myeloma cases in the region, growing awareness about treatment options, and the availability of advanced healthcare infrastructure. Doxorubicin is an effective cancer therapeutic drug used to treat multiple myeloma, as it can kill cancer cells while not damaging healthy cells. It also helps to reduce symptoms, such as pain and fatigue, associated with the condition. Additionally, the increasing expenditure on healthcare is also a major factor driving the growth of the doxorubicin market in Europe.
Companies Dominating the Doxorubicin Landscape
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Johnson and Johnson
- Zydus Group
- Cipla Limited
- Sun Pharmaceutical Industries Ltd
- Padagis
- Reddy Laboratories Ltd.,
- Cadila Healthcare Limited
- Novartis International AG
- MicroBiopharm Japan Co. Ltd.
In the News
- Ayana Pharma Ltd, in partnership with Padagis, received approval from the US FDA to launch a generic version of the drug Doxil (Doxorubicin Liposome Injection), which has been rated AB by the FDA.
- Under a definitive merger agreement between Pfizer Inc. and Seagen Inc., Pfizer Inc. plans to acquire Seagen for USD 229 per Seagen share, for a total enterprise value of USD 43 billion. Seagen develops, commercializes, and discovers transformative cancer medicines.
Author Credits: Radhika Pawar
- Report ID: 4876
- Published Date: May 09, 2025
- Report Format: PDF, PPT
